期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 23, 期 9, 页码 1233-1237出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543776.2013.820707
关键词
antibacterial; DNA gyrase; prodrugs; topoisomerase IV
The two patent applications describe two novel compounds in the benzimidazole class of GyrB/ParE antibacterial agents and multiple phosphate prodrugs derived from these compounds. The new benzimidazole compounds have excellent antibacterial activity on Gram-positive strains. But like previous benzimidazoles, they have limited solubility and are highly protein bound. The phosphate prodrugs offer a drug substance with high aqueous solubility that should aid both intravenous and oral formulations. The potential utility of the prodrugs was demonstrated in efficacy studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据